1xbet 다운로드 Pharmaceutical Co., Ltd.
Illum1xbet 다운로드a, 1xbet 다운로드c.

First use 1xbet 다운로드 Japan of a comprehensive genomic profil1xbet 다운로드g assay for blood cancers

1xbet 다운로드 Pharmaceutical Co., Ltd. (1xbet 다운로드) and Illumina, Inc. (Illumina; based in San Diego, Calif.) announce a collaboration to develop an in-vitro, diagnostic (IVD) genomic profiling testing kit for patients in Japan blood cancers.

Under the agreement, 1xbet 다운로드 will develop IVD tests, based on a genomic profiling assay in development, that will run on Illumina's NextSeq™ 550Dx system.

1xbet 다운로드 and Illumina's broad objective is to accelerate research and development that will provide clinical benefits such as more decisive information related to diagnosis, prognostic prediction and treatment--to both patients and health care providers. If Japan's regulatory authority approves the test, kit, the next-generation-sequencing (NGS)-based, IVD workflow will enhance patient access to genetic information and personalized medicine. Contingent on this approval, 1xbet 다운로드 will commercialize the test kit in Japan.

As additional 1xbet 다운로드formation on the NextSeq™ 550Dx sequenc1xbet 다운로드g system, 1xbet 다운로드 2018 Illum1xbet 다운로드a received product approval for it 1xbet 다운로드 Japan as a medical device. S1xbet 다운로드ce 2018, Illum1xbet 다운로드a has been expand1xbet 다운로드g its IVD portfolio 1xbet 다운로드 the country.

As additional background on the genomic profiling assay in development by 1xbet 다운로드 and the National Cancer Center of Japan, in early 2020 the company announced a research collaboration with the Center and several major hospitals in Japan to evaluate the assay. Notably, in 2020 the assay received the Japanese MHLW's SAKIGAKE (forerunner initiative) designation.